@article{boyer:inserm-03694904,
  TITLE = {{Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa}},
  AUTHOR = {Boyer, Sylvie and Baudoin, Ma{\"e}l and Nishimwe, Marie Lib{\'e}r{\'e}e and Santos, Melina and Lemoine, Maud and Maradan, Gwena{\"e}lle and Sylla, Babacar and Kouanfack, Charles and Carrieri, Patrizia and Mourad, Abbas and Rouveau, Nicolas and Moh, Raoul and Seydi, Moussa and Attia, Alain and Woode, Maame Esi and Lacombe, Karine},
  URL = {https://inserm.hal.science/inserm-03694904},
  JOURNAL = {{BMC Health Services Research}},
  PUBLISHER = {{BioMed Central}},
  VOLUME = {22},
  NUMBER = {1},
  PAGES = {303},
  YEAR = {2022},
  MONTH = Mar,
  DOI = {10.1186/s12913-021-07289-0},
  KEYWORDS = {Chronic hepatitis C ; Sofosbuvir ; Direct-acting antivirals ; Cost-effectiveness analysis ; Cameroon ; Senegal ; C{\^o}te d'Ivoire ; Cost-utility analysis},
  PDF = {https://inserm.hal.science/inserm-03694904/file/s12913-021-07289-0.pdf},
  HAL_ID = {inserm-03694904},
  HAL_VERSION = {v1},
}